Pura Vida Investments’s Cymabay Therapeutics CBAY Stock Holding History

Pura Vida Investments’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-56,000	Closed	-$76K	–	94
2016 Q1	$76K	Sell	56,000 -144,000	-72%	-$178K	0.03%	76
2015 Q4	$338K	Hold	200,000	–	–	0.14%	69
2015 Q3	$388K	Hold	200,000	–	–	0.22%	58
2015 Q2	$602K	Buy	+200,000	New	+$821K	0.31%	59

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pura Vida Investments's CBAY Position: Q2 2016 in Review

Pura Vida Investments sold out of Cymabay Therapeutics (CBAY) in Q2 2016, closing a stake of 56,000 shares — an estimated $76K sold.

Pura Vida Investments first reported a position in CBAY in Q2 2015 and held it in 4 quarters. The position peaked at $602K in Q2 2015. 26 funds tracked by Wall St. Rank hold CBAY as of Q2 2016.

Pura Vida Investments reported no remaining Cymabay Therapeutics position as of Q2 2016 after selling out during the quarter.
Pura Vida Investments sold 56,000 Cymabay Therapeutics shares in Q2 2016, an estimated $76K.
Pura Vida Investments first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 4 quarters.
Pura Vida Investments's Cymabay Therapeutics position peaked at $602K in Q2 2015.
26 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2016.

Based on Pura Vida Investments's 13F filing for Q2 2016, filed 15 Aug 2016.